Company performance
Add to research
Current Price
as of May 21, 2025$126.82
P/E Ratio
12.52
Market Cap
$18.58B
Description
Add to research
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Metrics
Add to research
Overview
- HQCambridge, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerBIIB
- Price$126.82-2.86%
Trading Information
- Market cap$18.58B
- Float99.83%
- Average Daily Volume (1m)1,686,237
- Average Daily Volume (3m)1,753,325
- EPS$10.15
Company
- Revenue$9.40B
- Rev growth (1yr)6.17%
- Net income$240.50M
- Gross margin65.22%
- EBITDA margin33.03%
- EBITDA$771.50M
- EV$24.08B
- EV/Revenue2.56
- P/E12.52
- P/S1.98
- P/B1.09
- Debt/Equity39.00
Documents
Add to research
SEC Filings
Factset Street Account
StreetAccount Consensus Metrics Preview - Biogen Q3 Earnings ($250.45, +0.95) (2023-11-06T16:51:17Z)
Earnings Calls
Factset